↓
 

Tag Archives: nivolumab/ipilimumab

Dr. Hossein Borghaei (Pt 2): Reflecting on Progress & Future Directions in Immunotherapy

Drs. Hossein Borghaei and host Jack West discuss long term outcomes in lung cancer with immunotherapy, potential utility of IO combinations, and when we can consider patients doing well on immunotherapy as cured if doing well beyond 5 years. (26:22)

Are Tumor Mutation Burden and Nivolumab/Ipilimumab Ready for Clinical Use? Insights from CheckMate 227 (BMIC-035)

Dr. Jack West reviews the CheckMate 227 trial, summarizing highlights from efficacy & side effects of nivolumab/ipilimumab (nivo/ipi) compared to standard doublet chemotherapy in patients with advanced NSCLC & high tumor mutational burden (TMB). (9:39)

Download MP3 Audio Version

Nivolumab/Ipilimumab vs. Chemo in High TMB Advanced NSCLC: Key Results from CheckMate 227 (BMIC-034)

Dr. Jack West reviews the CheckMate 227 trial, summarizing highlights from efficacy & side effects of nivolumab/ipilimumab (nivo/ipi) compared to standard doublet chemotherapy in patients with advanced NSCLC & high tumor mutational burden (TMB). (13:06)

Download MP3 Audio Version

↑